Product details:
| ISBN13: | 9780443224201 |
| ISBN10: | 044322420X |
| Binding: | Hardback |
| No. of pages: | 300 pages |
| Size: | 228x152 mm |
| Language: | English |
| 700 |
Category:
CRISPR-Cas-Based Genome Editing for Treating Human Diseases - Part B
Publisher: Academic Press
Date of Publication: 1 January 2025
Normal price:
Publisher's listprice:
EUR 122.00
EUR 122.00
Your price:
47 730 (45 457 HUF + 5% VAT )
discount is: 10% (approx 5 303 HUF off)
The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
Click here to subscribe.
Click here to subscribe.
Availability:
Not yet published.
Long description:
CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR -Cas systems for metabolic disorders, Recent progress in CRISPR -Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR -Cas systems for cataract and blindness, Advances in CRISPR -Cas systems for muscular dystrophy, Recent development in CRISPR -Cas systems for cardiac disease, Current approaches in CRISPR -Cas systems for diabetes, and much more.
Additional sections cover Advances in CRISPR -Cas systems for liver disease, Advances in CRISPR -Cas systems for lung disease, Advances in CRISPR -Cas systems for kidney diseases, Current progress in CRISPR -Cas systems for rare disease, Advances in CRISPR -Cas systems for heredity disease, Recent progress in CRISPR -Cas systems for neurological disorders, and CRISPR challenges in clinical developments.
Additional sections cover Advances in CRISPR -Cas systems for liver disease, Advances in CRISPR -Cas systems for lung disease, Advances in CRISPR -Cas systems for kidney diseases, Current progress in CRISPR -Cas systems for rare disease, Advances in CRISPR -Cas systems for heredity disease, Recent progress in CRISPR -Cas systems for neurological disorders, and CRISPR challenges in clinical developments.
Table of Contents:
Preface
Vijai Singh
1. Current approaches in CRISPR -Cas systems for metabolic disorders
DHRUV KUMAR
2. Recent progress in CRISPR -Cas systems for CRISPR for retinal diseases
Mayank Bansal
3. Recent progress in CRISPR -Cas systems for cataract and blindness
Suresh Ramakrishna
4. Advances in CRISPR -Cas systems for muscular dystrophy
Vancha Harish
5. Recent development in CRISPR -Cas systems for cardiac disease
Xin Wang
6. Current approaches in CRISPR -Cas systems for diabetes
L. Karthik
7. Advances in CRISPR -Cas systems for liver disease
Majid Mojarrad
8. Advances in CRISPR -Cas systems for lung disease
Suresh Ramakrishna
9. Advances in CRISPR -Cas systems for kidney diseases
Anil Bhanudas Gaikwad
10. Current progress in CRISPR -Cas systems for rare disease
Ajay Kumar I
11. Advances in CRISPR -Cas systems for heredity disease
DHRUV KUMAR
12. Recent progress in CRISPR -Cas systems for neurological disorders
Anand Krishna Tiwari
13. CRISPR challenges in clinical developments
Hossein Soltaninejad, Mohadeseh Khoshandam and Saman Hosseinkhani
Vijai Singh
1. Current approaches in CRISPR -Cas systems for metabolic disorders
DHRUV KUMAR
2. Recent progress in CRISPR -Cas systems for CRISPR for retinal diseases
Mayank Bansal
3. Recent progress in CRISPR -Cas systems for cataract and blindness
Suresh Ramakrishna
4. Advances in CRISPR -Cas systems for muscular dystrophy
Vancha Harish
5. Recent development in CRISPR -Cas systems for cardiac disease
Xin Wang
6. Current approaches in CRISPR -Cas systems for diabetes
L. Karthik
7. Advances in CRISPR -Cas systems for liver disease
Majid Mojarrad
8. Advances in CRISPR -Cas systems for lung disease
Suresh Ramakrishna
9. Advances in CRISPR -Cas systems for kidney diseases
Anil Bhanudas Gaikwad
10. Current progress in CRISPR -Cas systems for rare disease
Ajay Kumar I
11. Advances in CRISPR -Cas systems for heredity disease
DHRUV KUMAR
12. Recent progress in CRISPR -Cas systems for neurological disorders
Anand Krishna Tiwari
13. CRISPR challenges in clinical developments
Hossein Soltaninejad, Mohadeseh Khoshandam and Saman Hosseinkhani
